

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  45D2236424	<b>(X3) Date Survey Completed</b>  11/01/2022
<b>Name of Provider or Supplier</b>  Quest Diagnostics Oncology Consultants	<b>Street Address, City, State</b>  7121 South Padre Island Drive, Ste 119, Corpus Christi, TX	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D5893</b>	<p>POSTANALYTIC SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1299(b)(c)</p> <p>(b) The postanalytic systems quality assessment must include a review of the effectiveness of corrective actions taken to resolve problems, revision of policies and procedures necessary to prevent recurrence of problems, and discussion of postanalytic systems quality assessment reviews with appropriate staff. (c) The laboratory must document all postanalytic systems quality assessment activities.</p> <p>This STANDARD is not met as evidenced by: Based on review of patient records, the laboratory's UAT Checklist, and confirmed in interview of laboratory personnel, the laboratory's quality assurance plan failed to identify that the laboratory's address was not updated on 5 of 5 patient reports when it moved suites on October 28, 2022. The findings included: 1. Review of the laboratory's UAT Checklist dated October 28, 2022, signed by Technical Consultant 2 (as listed on Form CMS-209) stated under 'General Review', "Note: Review patient reports that may be provided to clients. Attach copies to this form. For standard sites review both QLS and QDRS reports. (QDRS reports can be generated by faxing or emailing the patient report from the QL to a local fax number or email address.)" The report went on to stated, "7. Name and address of performing laboratory" acceptance was marked as yes. 2. Review of 5 of 5 patient reports from November 1, 2022 listed the laboratory addresses's suite number as 101. The laboratory's suite number is 119. 3. The findings were confirmed in interview with Technical Consultant 1 and 2 (as listed on Form CMS-209) on November 1, 2022 at 11:10 hours in the laboratory. Key: CMS - Centers for Medicare and Medicaid Services</p>